Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...
GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.
Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...
The drug dupilumab (Dupixent) effectively clears up airways plugged by mucus during an asthma attack, researchers reported ...
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Regeneron Pharmaceuticals profit rose in the third quarter as products sales supported revenue growth. The biotechnology company on Tuesday posted a rise in net income to $1.46 billion, or $13.62 a ...
Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales(recorded by Sanofi) increased 27% ...
Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback